Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 6/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13086174 | 0.69 | ENPP2 (0.53) | ENPP2CA1CA2 | |
| SCHEMBL30544060 | 0.69 | ENPP2 (0.58) | ENPP2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL13086505 | 0.69 | ENPP2 (0.58) | ENPP2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL25338046 | 0.69 | ENPP2 (0.58) | ENPP2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL133861 | 0.69 | — | — | |
| SCHEMBL6042142 | 0.67 | NOTUM (0.77) | NOTUMFKBP5CRBNNSD2ABL1 | |
| SCHEMBL29419532 | 0.65 | ENPP2 (1.00) | ENPP2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL6091 | 0.65 | ENPP2 (1.00) | ENPP2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL5940 | 0.65 | ENPP2 (0.71) | ENPP2CA1CA2CA4CA6 | |
| SCHEMBL29444118 | 0.65 | ENPP2 (0.71) | ENPP2CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2021-05-04 | — | — | US | claimed |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2020-09-10 | — | — | US | claimed |
| EP-3377491-B1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2019-11-13 | — | — | EP | claimed |
| EP-3377491-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2018-09-26 | — | — | EP | claimed |
| EP-3170822-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2017-05-24 | — | — | EP | claimed |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| EP-4263546-B1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2025-07-02 | — | — | EP | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-3997096-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-20240092792-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-21 | — | — | US | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20130203985-A1 | 2-OXO-1,2-DIHYDROPYRIDIN-4-YLBORONIC ACID DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | US | disclosed |
| EP-2576570-A1 | 2-OXO-1,2-DIHYDROPYRIDIN-4-YLBORONIC ACID DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2013-04-10 | — | — | EP | disclosed |
| WO-2013006400-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2011149822-A1 | 2-OXO-1,2-DIHYDROPYRIDIN-4-YLBORONIC ACID DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | WO | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092792-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | ENPP2 418/4885NOTUM 2529/4885FKBP5 674/4885 |
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | ENPP2 881/4885NOTUM 2118/4885FKBP5 1119/4885 |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | ENPP2 874/4885NOTUM 4502/4885FKBP5 1116/4885 |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | ROCK1, RHOC, ROCK2 | ENPP2 718/4885NOTUM 3246/4885FKBP5 1447/4885 |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | ENPP2 2741/4885NOTUM 423/4885FKBP5 4190/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | ENPP2 4258/4885NOTUM 2770/4885FKBP5 2274/4885 |
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | ENPP2 4017/4885NOTUM 1958/4885FKBP5 1911/4885 |
| US-20130203985-A1 | 2-OXO-1,2-DIHYDROPYRIDIN-4-YLBORONIC ACID DERIVATIVES | CYP1B1, OXGR1, ODC1 | ENPP2 1513/4885NOTUM 3818/4885FKBP5 2806/4885 |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK3 | ENPP2 881/4885NOTUM 2118/4885FKBP5 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.